Performance of Dehydroepiandrosterone Sulfate and Baseline Cortisol in Assessing Adrenal Insufficiency
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgae855 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Ashley J Han und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA. Hauptthemen laut MEDLINE: Dehydroepiandrosterone Sulfate, Adrenal Insufficiency, Hydrocortisone. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
Context
Diagnosing adrenal insufficiency (AI) often requires complex testing, which can be time-consuming and expensive. Dehydroepiandrosterone sulfate (DHEAS) is a promising marker of hypothalamic-pituitary-adrenal axis function; however, its diagnostic performance has not yet been evaluated in a large-scale study.
Objective
Evaluate the performance of DHEAS and baseline cortisol in assessing AI.
Design
Single-center retrospective cohort study.
Setting
Referral center. Patients Adults who underwent cosyntropin stimulation testing (CST) between 2005 and 2023 and had DHEAS measured within 3 months prior to CST. Main Outcome Measures Area under receiver operating characteristic curve (AUROC) for DHEAS and baseline cortisol. Prevalence of AI based on various DHEAS and baseline cortisol concentrations.
Results
Among 1135 patients, 195 (17.2%) had AI. Both baseline cortisol and DHEAS independently had good diagnostic performance with AUROC 0.81 [95% confidence interval (CI) 0.77-0.84 and 0.81 (95% CI 0.78-0.85)], respectively. Time of CST performance had no significant effect on diagnostic accuracy of baseline cortisol while recent glucocorticoid use decreased diagnostic performance of DHEAS (AUROC 0.72 vs 0.83). Only 1.2% of patients with baseline cortisol ≥10 mcg/dL had AI based on CST. Among patients with baseline cortisol between 5 and 9.9 mcg/dL, only 1.3% had AI if DHEAS was ≥60 mcg/dL. Conversely, the majority (72.2%) of patients with both baseline cortisol <5 mcg/dL and DHEAS <25 mcg/dL were found to have AI.
Conclusion
DHEAS has good diagnostic performance in assessing AI. Measuring both baseline cortisol and DHEAS concentrations may eliminate the need for further dynamic testing in many patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.
- Department of Internal Medicine, Medstar Health, Baltimore, MD 21239, USA.
- Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, MN 55905, USA.
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.
- Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, USA.
ORCID-Profile: Ashley J Han, Lucinda M Gruber, Alicia Algeciras-Schimnich, Irina Bancos
Zitieren
APA
Han, A. J., Suresh, M., Gruber, L. M., Algeciras-Schimnich, A., Achenbach, S. J., Atkinson, E. J., & Bancos, I. (2025). Performance of Dehydroepiandrosterone Sulfate and Baseline Cortisol in Assessing Adrenal Insufficiency. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae855
Vancouver
Han AJ, Suresh M, Gruber LM, Algeciras-Schimnich A, Achenbach SJ, Atkinson EJ, et al. Performance of Dehydroepiandrosterone Sulfate and Baseline Cortisol in Assessing Adrenal Insufficiency. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae855
BibTeX
@article{Han2025,
author = {Han, Ashley J and Suresh, Malavika and Gruber, Lucinda M and Algeciras-Schimnich, Alicia and Achenbach, Sara J and Atkinson, Elizabeth J and Bancos, Irina},
title = {Performance of Dehydroepiandrosterone Sulfate and Baseline Cortisol in Assessing Adrenal Insufficiency},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgae855}
}
EUVIMED